Clinical trials: Relapsed/Refractory
Relapsed or Refractory Marginal Zone B-cell Lymphoma
131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma
Marginal zone B-cell lymphoma (MZL) is a lymphoma originated from B-cell in lymph node with variable differentiation status, which is distributed to a variety of organs.
- Trial name
- NCT01678404
- Testing
- 131I-rituximab
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Korea Cancer Center Hospital
Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma
131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Follicular lymphoma (FL) and mantle cell lymphoma (MCL) are rare lymphomas which consist of less than 5% of non-Hodgkin lymphoma in Korea.
- Trial name
- NCT01678417
- Testing
- 131I-rituximab
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Korea Cancer Center Hospital
Relapsed and Refractory Acute Leukemia
Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies
Patients with active acute leukemia have dismal prognoses even with allogeneic transplantation.Thus,new measures to enhance graft versus leukemia effect and reduce relapse rates are needed.
- Trial name
- NCT01385072
- Testing
- Double matched sibling transplantation
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Relapsed or Refractory Multiple Myeloma
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
This was a multicenter, open-label, single-arm phase 3B study of the combination lenalidomide plus pulse high-dose dexamethasone.
- Trial name
- NCT00478777
- Testing
- Lenalidomide, dexamethasone
- Where
- 48 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Celgene Corporation
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
This is an open-label, dose escalation study of intravenous ARQ 621 administered to patients with late-stage solid tumors or hematologic malignancies.
- Trial name
- NCT00825487
- Testing
- ARQ 621
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Relapsed or Refractory Hematological Malignancies
Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies
- Trial name
- NCT00904787
- Testing
- ENMD-2076
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- CASI pharmaceuticals, Inc.
Relapsed or Refractory Chronic Lymphoproliferative Disorders
Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders
This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative…
- Trial name
- NCT01224769
- Testing
- bendamustine +/- rituximab
- Where
- Italy
- Volunteers
- 109 people
- Sponsor
- Gruppo Italiano Studio Linfomi
Relapsed or Cisplatin-Refractory Germ Cell Cancer
Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer
The purpose of this study is to investigate the activity of SU011248 in subjects with cisplatin-refractory or multiply relapsed germ cell cancer. It is believed that SU011248 treatment may prove to increase disease response.
- Trial name
- NCT00371553
- Testing
- SU011248 (Sunitinib)
- Where
- 6 sites in Canada
- Volunteers
- 33 people
- Sponsor
- British Columbia Cancer Agency
Relapsed Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Summary Acute promyelocytic leukemia is defined by a characteristic morphology (AML FAB M3/M3v), by the specific translocation t(15;17) and its molecular correlates (PML/RARa and RARa/PML).
- Trial name
- NCT00196768
- Testing
- Arsenic trioxide, Trisenox
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- German AML Cooperative Group
Non-Hodgkin's Lymphoma, Relapsed Lymphoma
Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma
Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy.
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Low-Grade Lymphoma
- Trial name
- NCT00054808
- Testing
- gallium nitrate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Genta Incorporated